CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE

Aim. To study the use of CYP2C19 pharmacogenetic testing (PhGT) for personalization of antiplatelet therapy in patients with acute coronary syndrome (ACS) in routine practice.Material and methods. The study included 103 patients with ACS without indications for long-term anticoagulant therapy, which...

Descrición completa

Detalles Bibliográficos
Main Authors: A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina
Formato: Artigo
Idioma:English
Publicado: Столичная издательская компания 2017-12-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
acute coronary syndrome
pharmacogenetics
cyp2c19
clopidogrel
ticagrelor
clinical guidelines
Acceso en liña:https://www.rpcardio.online/jour/article/view/1564

Internet

https://www.rpcardio.online/jour/article/view/1564

Títulos similares